JP2022535195A5 - - Google Patents

Info

Publication number
JP2022535195A5
JP2022535195A5 JP2021568909A JP2021568909A JP2022535195A5 JP 2022535195 A5 JP2022535195 A5 JP 2022535195A5 JP 2021568909 A JP2021568909 A JP 2021568909A JP 2021568909 A JP2021568909 A JP 2021568909A JP 2022535195 A5 JP2022535195 A5 JP 2022535195A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
patient
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021568909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033438 external-priority patent/WO2020236736A1/en
Publication of JP2022535195A publication Critical patent/JP2022535195A/ja
Publication of JP2022535195A5 publication Critical patent/JP2022535195A5/ja
Priority to JP2025064503A priority Critical patent/JP2025106475A/ja
Withdrawn legal-status Critical Current

Links

JP2021568909A 2019-05-19 2020-05-18 収縮不全の処置 Withdrawn JP2022535195A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064503A JP2025106475A (ja) 2019-05-19 2025-04-09 収縮不全の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849936P 2019-05-19 2019-05-19
US62/849,936 2019-05-19
US201962852739P 2019-05-24 2019-05-24
US62/852,739 2019-05-24
PCT/US2020/033438 WO2020236736A1 (en) 2019-05-19 2020-05-18 Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064503A Division JP2025106475A (ja) 2019-05-19 2025-04-09 収縮不全の処置

Publications (2)

Publication Number Publication Date
JP2022535195A JP2022535195A (ja) 2022-08-05
JP2022535195A5 true JP2022535195A5 (enExample) 2023-05-31

Family

ID=70978663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568909A Withdrawn JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置
JP2025064503A Pending JP2025106475A (ja) 2019-05-19 2025-04-09 収縮不全の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064503A Pending JP2025106475A (ja) 2019-05-19 2025-04-09 収縮不全の処置

Country Status (16)

Country Link
US (2) US20220265629A1 (enExample)
EP (1) EP3972597A1 (enExample)
JP (2) JP2022535195A (enExample)
KR (1) KR20220009440A (enExample)
CN (1) CN114173782A (enExample)
AU (2) AU2020279710A1 (enExample)
BR (1) BR112021023074A2 (enExample)
CA (1) CA3138080A1 (enExample)
CL (1) CL2021003045A1 (enExample)
CO (1) CO2021015505A2 (enExample)
IL (1) IL288051A (enExample)
MX (2) MX2021014109A (enExample)
PE (1) PE20220426A1 (enExample)
SG (1) SG11202112723PA (enExample)
TW (2) TW202541801A (enExample)
WO (1) WO2020236736A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020315605A1 (en) 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
KR102752382B1 (ko) * 2019-09-20 2025-01-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도
IL298885A (en) * 2020-06-15 2023-02-01 Myokardia Inc Treatment of atrial function
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
US20250025460A1 (en) * 2021-12-02 2025-01-23 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP2014088342A (ja) * 2012-10-30 2014-05-15 Kowa Company Ltd ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤
PH12021553074A1 (en) * 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
LT3645002T (lt) * 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
WO2019006325A1 (en) * 2017-06-30 2019-01-03 Equalaire Systems, Inc. VENT CAP OF HUB CAP

Similar Documents

Publication Publication Date Title
JP2025106475A5 (enExample)
JP6810152B2 (ja) サクビトリルおよびバルサルタンの組合せの新規使用
JP2023529502A5 (enExample)
LINDE‐EDELSTAM et al. Longevity in patients with high degree atrioventricular block paced in the atrial synchronous or the fixed rate ventricular inhibited mode
TWI874399B (zh) 心縮功能障礙之治療
US20240091203A1 (en) Methods for treating non-obstructive hypertrophic cardiomyopathy
US20230233545A1 (en) Treatment of atrial dysfunction
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
WO2024097284A1 (en) Mavacamten and derivatives thereof for use in treating atrial dysfunction
JP2025525913A (ja) 閉塞性肥大型心筋症を治療するための方法
JP2021530517A5 (enExample)
Musat et al. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment
TH2101007135A (th) เภสัชภัณฑ์สำหรับการรักษาการทำหน้าที่ความผิดปรกติช่วงหัวใจบีบตัวและภาวะหัวใจ ล้มเหลวที่มีสัดส่วนการบีบตัวของหัวใจที่ลดลง
WO2022162021A1 (en) Verinurad compositions and methods of use
de la Cruz Seoane et al. Triaging the Clinical Dilemma of a Suicidal Attempt With Sotalol Overdose Presenting With Ventricular Tachycardia, Asystole, and Torsades de Pointes
JP2021020917A (ja) サクビトリルおよびバルサルタンの組合せの新規使用
Steffen et al. Prognostic impact of left ventricular dilatation in heart failure with mildly reduced ejection fraction
WO2012020377A1 (en) Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation
Preveden et al. Hypertrophic cardiomyopathy: Perspectives of drug therapy
Arroues et al. Hypertrophic Cardiomyopathy: A New Era in Targeted Therapy
Bhinder Targeting Myocardial Energetics in Nonobstructive Hypertrophic Cardiomyopathy (nHCM): The Role of Ninerafaxstat
Hazique et al. Targeting Myocardial Energetics in Nonobstructive Hypertrophic Cardiomyopathy (nHCM): The Role of Ninerafaxstat
HK40122885A (zh) 用於治疗阻塞性肥厚性心肌病的方法
Friedrich et al. Treatment of Chronic Heart Failure
HK40061292A (en) Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide